Loading stock data…
Recursion Pharmaceuticals (RXRX)
$3.69+0.17 (+4.83%)
After Hours$3.70+0.01 (+0.27%)· Last close Jun 29
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Recursion Pharmaceuticals, Inc. in the Healthcare sector is trading at $3.69 with a market capitalization of $1.7B. Wall Street consensus targets $6.64 (7 analysts), implying a +80.0% move over the next 12 months. The stock is currently 49% below its 52-week high of $7.18, remaining 10.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +80.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.30M↓ | $35.35M↑ | $4.98M↓ | $19.10M↑ | $14.82M |
| Gross Profit | -$6.19M↓ | $21.08M↑ | -$9.70M↓ | -$1.06M↑ | -$7.01M |
| Operating Income | -$128.50M↓ | -$108.33M↑ | -$172.20M↑ | -$176.23M↑ | -$191.37M |
| Net Income | -$117.50M↓ | -$108.12M↑ | -$162.25M↑ | -$171.90M↑ | -$202.49M |
Peer Comparison
JNJUNHPFE
Fundamentals
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.70B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-54.62%
Volume
Today's trading volume
22.83M
Recent News
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying
These aren't for the faint of heart.
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note
Recursion Pharmaceuticals (RXRX) closed at $3.23 in the latest trading session, marking a +2.22% move from the prior day.
1 of the Most Interesting AI Stocks in the Market Isn’t a Tech Company
Recursion Pharmaceuticals is trying to prove that AI’s next big winner can also come from biotech, and not just from the tech sector.
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $3.18, representing a -3.34% change from its previous close.
X-Energy (XE) Powers 13.5% as Cathie Wood Gobbles More Stake
X-Energy Inc. (NASDAQ:XE) is one of the 10 Stocks Stealing the Spotlight from Wall Street Giants. X-Energy saw its share prices increase by 13.50 percent on Monday to end at $21.10 apiece, mirroring the broader market optimism and Cathie Wood’s increased exposure to its stock. Last week, Wood’s global asset management, ARK Invest, announced that […]